JAMA Network
About The Study: This cross-sectional study found an increase in glucagon-like peptide 1 receptor agonist (GLP-1RA) prescriptions, with notable differences across subpopulations by insurance type, sex, and age. Tirzepatide and semaglutide grew the fastest, possibly due to their superior glycemic, weight loss, and guideline-emphasized cardiorenal benefits. Although GLP-1RAs are generally covered for type 2 diabetes (T2D), coverage for obesity is limited (e.g., Medicare excludes anti-obesity drugs). Off-label semaglutide (for T2D) use in the obesity-only group underscores access barriers.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
